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Abstract Malignant pleural mesothelioma (MPM) is
associated with a very poor prognosis. Unlike other solid
tumors, any type of planned surgery for MPM would be
cytoreductive rather than radical. There are two types of
surgery for MPM. Extrapleural pneumonectomy (EPP)
involves en bloc resection of the lung, pleura, pericardium,
and diaphragm. Pleurectomy/decortication (P/D) is a lung-
sparing surgery that removes only parietal/visceral pleura.
In comparison with EPP, P/D is theoretically less radical
but is associated with less perioperative mortality/morbid-
ity and less postoperative deterioration of cardiopulmonary
function. It still remains unclear which surgical technique
is superior in terms of the risk/benefit ratio. In this context,
selection between EPP and P/D has been a matter to
debate.
Keywords Malignant pleural mesothelioma  Surgery 
Extrapleural pneumonectomy  Pleyrectomy/decortication 
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Introduction
Malignant pleural mesothelioma (MPM) is associated with
a very poor prognosis, and its incidence is expected to
increase in Asia and developing countries [1–6]. Because
any type of planned surgery would be cytoreductive rather
than radical [7], an optimal outcome via surgery alone is
unlikely [8]. Accordingly, the current strategy for curing
this disease has shifted to multimodal therapy with che-
motherapy and/or radiation therapy (RT).
There are two types of surgery for MPM. Extrapleural
pneumonectomy (EPP) involves en bloc resection of the
lung, pleura, pericardium, and diaphragm. Pleurectomy/
decortication (P/D) is a lung-sparing surgery that removes
only parietal/visceral pleura. EPP leaves less residual
tumor cells compared with P/D; however, it often results in
high mortality/morbidity, severe depression of cardiore-
spiratory function, and poor quality of life. Till date, the
risk–benefit ratios of P/D and EPP as part of multimodal
therapy have not been clearly elucidated.
Furthermore, the decision to perform either EPP or P/D
in studies on multimodal approaches has been solely based
on surgical conjecture and bias, rather than scientific data
[9].
EPP and P/D surgical procedures
The first set of procedures are common between EPP and
P/D [10] (shown as Step 1 in Fig. 1). Step 1 involves
thoracotomy, extrapleural dissection of the parietal pleura,
with diaphragm and/or pericardium resection if required,
and systematic lymph node dissection. Therefore, after
completing step 1, the lung/pleura block is connected to the
body only by hilar components, namely the main bronchus,
main pulmonary artery, and pulmonary veins. The second
set of procedures involve en bloc extirpation of lung,
parietal/visceral pleura, diaphragm, and pericardium in
EPP (Step 2a) and visceral pleurectomy in P/D (Step 2b).
Microscopic complete resection (R0) is theoretically
impossible in Step 1 and Step 2b, but not in Step 2a. Step
2b is more likely to leave residual tumor cells compared
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with Step 1 because connection between the visceral pleura
and lung parenchyma is usually tighter than that between
the parietal pleura and chest wall. Therefore, P/D is less
radical compared with EPP [11].
On the other hand, EPP has several disadvantages such
as higher perioperative mortality/morbidity, severe deteri-
oration of postoperative cardiopulmonary function and
quality of life, and poorer tolerance to chemotherapy in
case of recurrence.
Therefore, selection between EPP and P/D leads to the
selection of the radicality of Step 2a over that of Step 2b or
the selection of less surgical insult from P/D over that from
EPP (Fig. 2).
Confusion and unanswered questions regarding MPM
treatment
An element of extreme confusion exists with regard to
MPM treatment, particularly surgery. The proposed rea-
sons are mentioned below.
Questionable survival benefit of surgery
Different surgical procedures with curative intent can exist
for malignant disease, such as lobectomy and segmentec-
tomy for primary lung cancer. However, the situation is
quite different for MPM surgery. Unlike the goal of surgery
for other solid tumors, the goal of MPM surgery is not
radical resection but macroscopic complete resection
(MCR) because of the lack of surgical margins [7, 12].
Recently, Treasure et al. [13] concluded from the Meso-
thelioma and Radical Surgery (MARS) feasibility study
that radical surgery in the form of EPP within trimodality
therapy offered no benefit. However, apt interpretation of
the MARS study remains debatable [14–19].
Why is survival after P/D equal to or even better
than that after EPP
Theoretically, P/D is less radical than EPP, even though
both are only cytoreductive procedures. However, most
hospitals have reported equal or even better survival after
P/D than after EPP [20–23]. In the context of multimodal
therapy, Cao et al. [24], on the basis of their meta-analysis,
concluded that selected patients who underwent extended
P/D had lower perioperative morbidity and mortality with
similar, if not superior, long-term survival compared with
those who underwent EPP. Furthermore, Lucklatz and
others [22] reported that P/D combined with postoperative
adjuvant therapy provided better survival compared with
EPP, irrespective of factors such as advanced disease or
surgically less fit patients.
Other than nonprospective settings and patient selection
bias, there may be several explanations for this
contradiction.
First, EPP is associated with higher perioperative mor-
tality/morbidity. Cao et al. conducted a systematic analysis
and demonstrated that perioperative mortality (2.9 vs.
6.8 %, p = 0.02) and morbidity (27.9 vs. 62.0 %,
p \ 0.0001) were significantly lower for patients who
underwent extended P/D than for those who underwent
EPP [24]. Second, patients who undergo P/D have more
opportunities for additional therapy after recurrence com-
pared with patients who undergo EPP. Bolukbas et al. [25]
found that additional chemotherapy after recurrence was
Fig. 1 Diagram of surgical procedures in EPP and P/D. Step 1
comprises the common procedures in EPP and P/D, including
thoracotomy, extrapleural dissection of the parietal pleura, with
diaphragm and/or pericardium resection if required, and systematic
lymph node dissection. Steps 2a and 2b represent other surgical
options
Fig. 2 Comparison of disadvantages between EPP and P/D. EPP is
associated with high perioperative mortality/morbidity and severe
deterioration of postoperative cardiopulmonary function and quality
of life. On the other hand, P/D leaves more residual tumor cells
because of visceral pleurectomy. Selection between EPP and P/D
ultimately leads to the selection of the radicality of Step 2a over that
of Step 2b or the selection of less surgical insult from P/D over that
from EPP
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acceptable in 64 % patients who initially underwent P/D
and 25 % patients who initially underwent EPP. Accord-
ingly, survival after recurrence was longer in patients who
underwent P/D than in those who underwent EPP [15, 23].
Third, because of better cardiopulmonary reserve, patients
who undergo P/D are more equipped to fend off postop-
erative nononcological disorders such as pneumonia and
cardiac failure compared with those who undergo EPP.
Because there is no randomized study comparing EPP
and P/D, it remains unclear whether postoperative survival
in P/D patients is really equal to or better than that in EPP
patients.
Ambiguity surrounding the definition of P/D
Although P/D has been performed for more than 30 years,
confusion still surrounds the actual meaning of pleurec-
tomy/decortication. Recently, the International Mesotheli-
oma Interest Group (IMIG), in collaboration with the
International Association for the Study of Lung Cancer
(IASLC), published a Consensus Report that classified
pleurectomy into three categories according to surgical
technique [26].
1. Extended P/D: parietal and visceral pleurectomy to
remove all gross tumor, with resection of the dia-
phragm and/or pericardium.
2. P/D: parietal and visceral pleurectomy to remove all
gross tumor, without resection of the diaphragm or
pericardium.
3. Partial pleurectomy: partial removal of parietal and/or
visceral pleura for diagnostic or palliative purposes,
leaving gross tumor behind.
However, several critical points remain unclear.
First, does P/D allow part of the pleura to be left behind
as long as it contains no macroscopic tumor? The con-
sensus report does not mandate that P/D include 100 %
visceral pleurectomy; it requires only MCR or complete
resection of macroscopic tumors. The National Compre-
hensive Cancer Network (NCCN) guidelines clearly define
P/D as complete removal of involved pleura and all gross
tumor [27]. This distinction is particularly important in
cases of early MPM, in which 100 % resection of almost
intact visceral pleura is technically difficult. Second, the
consensus states that resection of the diaphragm and/or
pericardium is not mandatory in extended P/D; however, it
should be performed if required. If so, what does P/D
indicate? In cases involving the diaphragm and/or peri-
cardium, pleurectomy without resection of the diaphragm
and/or pericardium should be categorized as partial pleur-
ectomy instead of P/D. I would propose that extended P/D
and P/D be redefined as P/D, which involves parietal and
visceral pleurectomy to remove all gross tumor, with
resection of the diaphragm and/or pericardium if required.
By changing the meaning of P/D in terms of diaphragm
and/or pericardium involvement, a more comprehensible
and consistent definition will be realized.
Third, does P/D allow the resection of pulmonary
parenchyma? Lang-Lazdunski and colleagues [28] reported
that 12 % (5/41) P/D patients required either lobectomy or
segmentectomy. Also, an ongoing multicenter phase II
study in Japan permits the resection of pulmonary paren-
chyma [29].
Discrepancy among guidelines
The NCCN guidelines recommend surgical resection for
patients with clinical stage I–III MPM who are medically fit
for and can tolerate surgery [27]. The NCCN guidelines also
recommend that P/D should be the first option for early
disease (confined to the pleural envelope, no N2 lymph
node involvement) with favorable histology (epithelioid).
In Europe, both the European Respiratory Society
(ERS)/European Society of Thoracic Surgery (ESTS) [30]
and British Thoracic Society (BTS) [31] guidelines state
that the role of surgical resection in MPM is very uncertain
and that radical surgery should only be performed in
clinical trials, in specialized centers, and as part of a
multimodal treatment plan. They also state that P/D should
not be proposed with a curative intent. Italian guidelines
recommend EPP to achieve adequate local control of MPM
and P/D for patients with minimal, early-stage disease [32].
Therefore, discrepancies concerning performance prac-
tices and recommendations for P/D and EPP clearly exist.
Furthermore, many MPM centers in Europe and some in
North America and Japan are currently performing P/D
with curative intent [20, 21, 28, 29, 33–37].
Should the surgical techniques for MPM ever be refined,
the arrant inconsistencies cited above must be identified
and resolved as soon as possible.
Very recently, the attendees of the 2012 International
Mesothelioma Interest Group Congress agreed that the type
of surgery (EPP or P/D), as long as it pertains to MCR,
shall depend on clinical factors and the surgeon’s indi-
vidual judgment and expertise [17]. This concept would
seem to hold much promise.
Scarcity of prospective clinical studies on P/D
With regard to EPP, one phase III study [13] and several
phase II studies have been reported till date [38–42].
Therefore, the MCR completion rate and overall survival
for intent-to-treat patients can be calculated.
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With regard to P/D, however, there are few completed
phase II studies [43, 44] and a few ongoing phase II studies
[29, 45]. Rusch et al. [43] reported in their phase II study
that MPM was resectable in 78 % (28/36) patients. How-
ever, they did not describe the MCR completion rate. An
ongoing Japanese phase II study is designed to observe the
feasibility of induction chemotherapy using pemetrexed
plus cisplatin followed by P/D in patients with resectable
MPM [29]. This study appears promising in that it will
clarify the MCR completion rate as well as the conversion
rate from P/D to EPP.
RT after P/D
Unlike in EPP, external beam radiation therapy following
P/D has been contraindicated because of possible damage
to the preserved ipsilateral lung [30, 46, 47].
Very recently, however, a few authors reported suc-
cessful RT after P/D. Minatel et al. administered 50 Gy
of hemithoracic radiation with helical tomotherapy fol-
lowing radical P/D. This protocol resulted in a median
survival time of 33 months, progression-free survival of
29 months, and a 3-year survival rate of 49 %, with no
fatal toxicity. [48] There is an ongoing phase II study at
Memorial Sloan-Kettering Cancer Center in which
hemithoracic pleural intensity-modulated radiation ther-
apy (IMRT; 50.4 Gy in 28 fractions) is administered
after induction chemotherapy and P/D [45]; an interim
analysis found that this protocol had an acceptable tox-
icity [49].
From these observations, one can speculate that the
reintroduction of RT after P/D can result in better local
control and longer postoperative survival.
Selection between EPP and P/D
There exist some cases for which only one type of surgery
is indicated. For example, patients with poor cardiopul-
monary function are only fit for P/D. In patients with bulky
and deep invasion to the pulmonary parenchyma, MCR can
be achieved only by EPP. In the remaining cases, surgeons
have to choose either EPP or P/D. Two different approa-
ches are currently employed in patients with stage I–III
resectable MPM who can tolerate aggressive surgery.
Selection of surgery on an individual basis
Some surgeons recommend tailoring of the surgical pro-
cedure to intraoperative findings, with the ultimate goal of
achieving MCR using the procedure with the least mor-
bidity [9, 50]. These surgeons elect to perform P/D in
patients with minimal disease [9, 51]. P/D is also recom-
mended if essential mediastinal structures (e.g., aorta and
vertebral bodies) are found to be involved at thoracotomy
[52].
This approach is accepted by most MPM centers in
North America and Japan, as well as by some European
centers [17].
Preference of P/D
Although European guidelines advise that P/D should not
be proposed with a curative intent [30, 31], an increasing
number of centers have abandoned EPP and consider P/D
with a curative intent as their basic approach toward
resectable MPM [28, 35, 37, 53]. The feasibility of P/D in
Fig. 3 Current approach to
resectable MPM at Hyogo
College of Medicine. We are
currently choosing the least
invasive surgical procedures to
achieve MCR. P/D is indicated
in most cases, except those with
extensive tumor invasion to the
pulmonary parenchyma.
Resection of the diaphragm,
pericardium, and lung
parenchyma is performed if
required. Conversion to EPP
from P/D is decided on the basis
of intraoperative findings
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patients with advanced MPM may be questionable. Fried-
berg and others reported an MCR rate of 97 % (37/38) and
a median survival of 21 months in their series of radical
pleurectomy with intraoperative photodynamic therapy for
advanced MPM. On the basis of their results, they theo-
rized that MCR could be achieved with radical pleurec-
tomy in all MPM cases in which MCR could be achieved
with EPP [53]. Bolukbas et al. [54] reported that an MCR
rate of 61.9 %, a surgical mortality of 4.8 %, a median
survival of 21 months, and a 5-year survival of 28 % were
achieved in patients with stage III MPM treated by tri-
modality therapy with radical pleurectomy.
Current approach to resectable MPM at Hyogo College
of Medicine (Fig. 3)
As mentioned above, we are currently selecting the least
invasive surgical procedures for achieving MCR. There-
fore, surgery is initiated with the intention of performing
P/D, with the exception of some cases with extensive
invasion of MPM to the pulmonary parenchyma. Resection
of the diaphragm and/or pericardium is performed only
after all efforts to preserve them fail. Although an ongoing
Japanese feasibility study permits the sparing of the vis-
ceral pleura as long as it does not contain macroscopic
tumor [29], we remove all the parietal/visceral pleura
irrespective of the presence of macroscopic lesions. Lung
resection is frequently performed during P/D to achieve
MCR and/or decrease air leakage.
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